Drug Database
Back to search

Germany· DE-A57-41ad84f05b6109eb

Tirofiban Ibisqus

A tirofiban product containing tirofiban, registered in Germany by Ibigen Srl. The same ATC class is registered in 11 of our 19 countries.

ATC B01AC17

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedTirofiban IbisqusATCB01AC17REGISTER NO.DE-A57-41ad84f05b6109…PACKS LISTED0CHECKEDSeptember 30, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tirofibanAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tirofiban is registered in 11 of 19 countries.

Countries holding a registration under ATC B01AC17 (tirofiban), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 7 of them publish a price we can compare per daily dose
Search tirofiban products by name

Tirofiban · ATC B01AC17

11 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Tirofiban
Manufacturer
Ibigen Srl
Country
Germany (DE)
ATC code
B01AC17
ATC class
Tirofiban
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

159 interactions on record for tirofiban.

Graded by severity as the source publishes them — 62 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tirofiban against other medicinesHow interaction checks work

Tirofiban · interactions on record

159 records

  • 62 severe
  • 75 moderate
  • 22 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tirofiban in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tirofiban products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Aggrastat
  • Belgium · Aggrastat
  • Bulgaria · Аграстат, Тирофибан Чайкафарма
  • Cyprus · Aggrastat, Αggrafiban
  • Estonia · Aggrastat
  • Spain · Agrastat, Tirofiban Altan Pharmaceuticals S.A.
  • Finland · Aggrastat
  • France · Agrastat, Tirofiban Altan
  • United Kingdom (Northern Ireland) · Aggrastat, Tirofiban Eugia (Uk)
  • Greece · Aggrastat, Αggrafiban
  • Hungary · Aggrastat
  • Italy · Aggrastat, Tirofiban Aurobindo
  • Lithuania · Aggrastat
  • Luxembourg · Aggrastat
  • Latvia · Aggrastat
  • Malta · Aggrastat, Tirofiban Ibigen
  • Netherlands · Aggrastat, Tirofiban Eugia
  • Portugal · Tirofibano, Tirofibano Generis
  • Sweden · Aggrastat

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f6ae6e5d-0b7e-43b9-968c-0898aa25d3a2
GET /v1/drugs/f6ae6e5d-0b7e-43b9-968c-0898aa25d3a2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Tirofiban",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}
API referenceMCP serverPlans

See everything about tirofiban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console